Cingulate Inc.
$3.70
Stock Quotes & Analysis
CING2.63%
$3.70
Latest AAPL News (Need to figure out how to make this dynamic)
test
Graphene is an excellent conductor of electricity and heat, surpassing traditional materials like silicon, and…
The political winds are shifting, and Wall Street is taking notice. As Donald Trump’s approval…
In the shadows of Silicon Valley’s AI frenzy, a sleeping giant is awakening. While tech…
Cingulate Inc.Status: Active
Sector: Healthcare
Industry: Biotechnology
Symbol: CING
Exchange: NCM
Employees: 13
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
 | 1901 West 47th Place, Kansas City, KS, United States |
 | 913 942 2300 |
 | https://www.cingulate.com |